To advance St.Louis’ regional prosperity by cultivating a thriving biosciences sector. BioGenerator pursues this mission by building and investing in a robust pipeline of successful bioscience companies and entrepreneurs.
October 29, 2002
The “St. Louis Life Sciences Development Center” is incorporated by the Coalition for Plant and Life Sciences (later renamed BioSTL), as part of a comprehensive regional strategy for strengthening St. Louis’ bioscience innovation and entrepreneurship ecosystem. The Coalition for Plant and Life Sciences, founded and led by Dr. William Danforth, Chancellor Emeritus of Washington University in St. Louis, is comprised of the region’s top university, business, civic and philanthropic leaders, committed to establishing the infrastructure to capitalize on St. Louis’ unique strengths in medical and plant biosciences.
St. Louis Life Sciences Development Center renamed “BioGenerator.”
BioGenerator moves to CIC@CET.
BioGenerator hires new leadership team of Eric Gulve, President, Dan Broderick and Charlie Bolten, Vice Presidents
Launch of Pre-Seed Fund.
BioGenerator launches the BioGenerator Labs in the Cortex-1 building.
BioGenerator secures 1 of 6 national Challenge awards from U.S. Dept. of Commerce, the National Institutes of Health, and the National Science Foundation designed to reward the most innovative ideas to drive technology commercialization and entrepreneurship in regions. BioGenerator led execution of the program, which launched 13 new companies.
BioGenerator’s founding organization, the Coalition for Plant and Life Sciences, is reorganized under the name “BioSTL.” Multi-year financial commitments to BioSTL are announced by Washington University in St. Louis, BJC HealthCare, and St. Louis Life Science Project (an entity supported by St. Louis philanthropists Dr. William Danforth and John McDonnell).
BioGenerator expands its Entrepreneur in Residence (EIR) program with an award from the U.S. Dept. of Commerce’s Jobs & Innovation Accelerator Challenge.
BioGenerator reorganized as subsidiary of BioSTL, its funding organization.
Galera Therapeutics, previously launched with seed funding by BioGenerator, announces $11 million Series A financing.
BioGenerator portfolio companies cross the $100 million mark in additional, private investments attracted.
BioGenerator investment moves Agtech startup Benson Hill to St. Louis.
Launch of Post-Seed Fund.
BioGenerator investment moves Adarza BioSystems to St. Louis.
BioGenerator expands Labs facility to triple its size.
BioGenerator completes its 50th investment.
BioGenerator portfolio company Kogent Surgical announces Worldwide Distribution Agreement with Medtronic Surgical Technologies.
BioGenerator launches Agtech startup Arvegenix with Pre-Seed funding.
BioGenerator portfolio companies cross the $300 million mark in additional, private investments attracted.
BioGenerator launches YourBevCo, a beverage device company.
Cardialen, previously launched with BioGenerator seed funding, announces Series A financing and clinical development plans
BioGenerator portfolio company Apse announces seed financing and appointment of new CEO.
BioGenerator leads initial funding round for Healthcare IT startup Epharmix.
BioGenerator increases investment in Confluence Life Sciences to $900K.
MediBeacon, previously launched with BioGenerator seed funding, announces $22.4 million Series A financing.
BioGenerator portfolio company SynerZ Medical is acquired in a private transaction.
David Smoller, founder of successful startups ProteoPlex, Genome Systems, and SAGE Labs, and David Christenson, co-founder of the successful startup LDM Group, join BioGenerator as an Entrepreneurs in Residence.
BioGenerator is among the first 17 recipients, out of 240 applicants, of a $500,000 grant from the 2014 Regional Innovation Strategies program to create the St. Louis Regional Bioscience Proof of Concept Center.
BioGenerator pre-seed investment helps S4 Agtech establish US operations at St. Louis’ Helix Center.
BioGenerator Fundamentals and Grants2Business programs formalized; industry veteran Harry Arader hired to direct new programs.
BioGenerator portfolio companies cross the $400 million mark in additional, private investments attracted.
Pulse Therapeutics, previously launched with BioGenerator seed funding, announces $10M financing.
With investment from BioGenerator, Agtech startup Edison Agrosciences moves to St. Louis.
BioGenerator increases investment in Confluence Life Sciences to $1.4M, making the company BioGenerator’s largest cumulative investment.
Tioma Therapeutics, previously launched with seed funding by BioGenerator and based on technology developed at Washington University in St. Louis, announces $86 million Series A financing.
Former Co-Founder and President of SAGE Labs, Edward Weinstein, joins BioGenerator as an Entrepreneur in Residence.
Galera Therapeutics, previously launched with BioGenerator seed funding, announces $57 million Series B financing.
BioGenerator investment catalyzes newly formed Indalo Therapeutics.
BioGenerator launches new research tools company Canopy Biosciences.
Adarza BioSystems, previously recruited to St. Louis with a BioGenerator seed investment, announces $17M Series B financing.
Benson Hill BioSystems announces $25M Series B financing. The company was recruited to St. Louis in 2013 with Seed financing led by BioGenerator.
Previously launched with BioGenerator pre-seed investment and BioGenerator’s largest single investment at $1.4M in cumulative capital, Confluence Life Sciences acquired by Aclaris Therapeutics for up to $100M.
BioGenerator Fundamentals and Grants programs support the formation of new companies SentiAR and Plastomics, which both announce initial financing rounds.
BioGenerator Labs, a unique wet lab co-working resource, reaches milestone of 200th active client.
BioGenerator Grants program reaches milestone with 35th pre-investment grant awarded. Notable companies that received BioGenerator Grants prior to funding from any other source include Canopy Biosciences, SentiAR, Kalocyte, Plastomics, Unleash Immuno Oncolytics, Precision Virologics, and DiSARM Therapeutics.